In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes

References

• Byun JY, Kim MJ, Eum DY, et al. (2009). Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol 76:734–44.
   PubMed Web of Science ®Google Scholar
• Carvalho PR, Silva DH, Bolzani VS, Furlan M. (2005). Antioxidant quinonemethide triterpenes from Salacia campestris. Chem Biodivers 2:367–72.
   PubMed Web of Science ®Google Scholar
• Chicca A, Marazzi J, Gertsch J. (2012). The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors. Br J Pharmacol 167:1596–608.
   PubMed Web of Science ®Google Scholar
• Costa PM, Ferreira PM, Bolzani Vda S, et al. (2008). Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol in Vitro 22:854–63.
   PubMed Web of Science ®Google Scholar
• Deeb D, Gao X, Liu YB, et al. (2014). Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2. Int J Oncol 44:1707–15.
   PubMed Web of Science ®Google Scholar
• Dirsch VM, Kiemer AK, Wagner H, Vollmar AM. (1997). The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol 336:211–17.
   PubMed Web of Science ®Google Scholar
• Dong C, Xu C, Liu H, et al. (2015). Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method. Fitoterapia 106:62–7.
   PubMed Web of Science ®Google Scholar
• Dos Santos VA, Leite KM, da Costa Siqueira M, et al. (2013). Antiprotozoal activity of quinonemethide triterpenes from Maytenus ilicifolia (Celastraceae). Molecules 18:1053–62.
   PubMed Web of Science ®Google Scholar
• Ericsson T, Sundell J, Torkelsson A, et al. (2014). Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica 44:615–26.
   PubMed Web of Science ®Google Scholar
• Eum DY, Byun JY, Yoon CH, et al. (2011). Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction. Anticancer Drugs 22:763–73.
   PubMed Web of Science ®Google Scholar
• Hu X, Huang W, Yang Y. (2015). Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii. Eur J Drug Metab Pharmacokinet 40:373–7.
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, et al. (1998). Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461–99.
   PubMed Web of Science ®Google Scholar
• Jeong HU, Kong TY, Kwon SS, et al. (2013). Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 18:10681–93.
   PubMed Web of Science ®Google Scholar
• Lang J, Li W, Zhao J, Wang K, Chen D. (2017). Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica 47:849–55.
   PubMed Web of Science ®Google Scholar
• Li AP. (2001). Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today 6:357–66.
   PubMed Web of Science ®Google Scholar
• Lim YP, Chen WC, Cheng CH, et al. (2014). Inhibition of cytochrome P450 2C9 expression and activity in vitro by allyl isothiocyanate. Planta Med 80:1097–106.
   PubMed Web of Science ®Google Scholar
• Liu T, Qian G, Wang W, Zhang Y. (2015). Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole. Eur J Drug Metab Pharmacokinet 40:235–8.
   PubMed Web of Science ®Google Scholar
• Lu Z, Jin Y, Chen C, et al. (2010). Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer 9:112.
   PubMed Web of Science ®Google Scholar
• Mejia-Manzano LA, Barba-Davila BA, Gutierrez-Uribe JA, et al. (2015). Extraction and Isolation of Antineoplastic Pristimerin from Mortonia greggii (Celastraceae). Nat Prod Commun 10:1923–8.
   PubMed Web of Science ®Google Scholar
• Meng Q, Liu K. (2014). Pharmacokinetic interactions between herbal medicines and prescribed drugs: focus on drug metabolic enzymes and transporters. Curr Drug Metab 15:791–807.
   PubMed Web of Science ®Google Scholar
• Pandit S, Mukherjee PK, Ponnusankar S, et al. (2011). Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6. Fitoterapia 82:369–74.
   PubMed Web of Science ®Google Scholar
• Pirotta M, Willis K, Carter M, et al. (2014). ‘Less like a drug than a drug': the use of St John's wort among people who self-identify as having depression and/or anxiety symptoms. Complement Ther Med 22:870–6.
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, et al. (2013). Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol 56:392–7.
   PubMed Web of Science ®Google Scholar
• Scalvini L, Piomelli D, Mor M. (2016). Monoglyceride lipase: structure and inhibitors. Chem Phys Lipids 197:13–24.
   PubMed Web of Science ®Google Scholar
• Shimada T, Mimura M, Inoue K, et al. (1997). Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401–8.
   PubMed Web of Science ®Google Scholar
• Singh AP, Pant MC, Ruwali M, et al. (2010). Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark 8:351–9.
   PubMed Web of Science ®Google Scholar
• Unger M. (2013). Pharmacokinetic drug interactions involving Ginkgo biloba. Drug Metab Rev 45:353–85.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhou SF. (2009). Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem 16:4066–218.
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. (1992). The human hepatic cytochromes P450 involved in drug metabolism. Criti Rev Toxicol 22:1–21.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chan ML, Chen WY, et al. (2005). Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther 4:1277–85.
   PubMed Web of Science ®Google Scholar
• Yadav VR, Prasad S, Sung B, et al. (2010). Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel) 2:2428–66.
   PubMed Web of Science ®Google Scholar
• Yan Z, Caldwell GW. (2001). Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem 1:403–25.
   PubMedGoogle Scholar
• Yang H, Landis-Piwowar KR, Lu D, et al. (2008). Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem 103:234–44.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ya G, Rui H. (2016). Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-glycoprotein. Eur J Drug Metab Pharmacokinet 42:89–98.
   Web of Science ®Google Scholar
• Zhang JW, Liu Y, Cheng J, et al. (2007). Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci 10:496–503.
   PubMed Web of Science ®Google Scholar
• Zhang QH, Hu JP, Wang BL, Li Y. (2012). Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res 14:382–95.
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu S, Wang Y, et al. (2015). Effects of curculigoside on memory impairment and bone loss via anti-oxidative character in APP/PS1 mutated transgenic mice. PLoS One 10:e0133289
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Li SC, et al. (2004). Predicting pharmacokinetic herb–drug interactions. Drug Metabol Drug Interact 20:143–58.
   PubMedGoogle Scholar
• Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310–22.
   PubMed Web of Science ®Google Scholar